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Abstract 
 
Mxi1 belongs to the Myc-Max-Mad transcription factor network.  Two Mxi1 
protein isoforms, Mxi1-SRα  and Mxi1-SRβ , have been described recently to share 
many biological properties.  Here we assign differential functions to these isoforms with 
respect to two distinct levels of Myc antagonism. Unlike Mxi1-SRβ, Mxi1-SRα  is not a 
potent suppressor of the cellular transformation activity of Myc. Furthermore, while 
Mxi1-SRβ  exhibits a repressive effect on the MYC promoter in transient expression 
assays, Mxi1-SRα  activates this promoter. A specific domain of Mxi1-SRα  contributes 
to these differences. Moreover GAPDH interacts with Mxi1-SRα  and enhances its 
ability to activate the Myc promoter. Our findings suggest that mxi1 gains functional 
complexity by encoding isoforms with shared and distinct activities.  
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Introduction 
 
 Members of the Myc oncoprotein family function as transcription factors that control 
various aspects of cellular behavior including cell growth, proliferation, differentiation, 
apoptosis, genomic stability, and tumorigenesis (reviewed recently in [1-4]).  Deregulation of 
Myc contributes to the pathogenesis of a large proportion of human cancers (reviewed in 
[5,6]).  This deregulation has been shown to occur at multiple levels including those that 
affect myc gene expression, Myc protein stability, and Myc biological activity.  Normal 
regulation of Myc activity occurs by mechanisms that influence the Myc protein per se (for 
examples see [7]), and also through the functions of related members of the extended Myc-
Max-Mad protein network (reviewed recently in [8]; note that the Mad subfamily recently 
has been renamed the Mxd subfamily).  
The Mxi1 (a.k.a. Mxd2) protein first was described as a member of the 
Myc/Mad/Max network by virtue of its having a basic helix-loop-helix leucine zipper 
(bHLH/LZ) region similar to that of Myc and of its interaction with the obligate Myc DNA 
binding partner, Max [9].  In early models that defined Mxi1’s function within this network, 
Mxi1 (as well as the related Mad family proteins) was proposed to be a Myc antagonist.  This 
was based upon its ability to bind competitively with Myc both to the Max protein and, once 
complexed with Max, to shared DNA sequence motifs (E-boxes; CANNTG).  Beyond this, it 
was realized that whereas Myc could transactivate gene expression at the E-box through the 
recruitment of various co-activators (see [2] and references therein), Mxi1 could repress gene 
expression there through its interaction with Sin3/HDAC (histone deacetylase) complexes 
([10,11] and reviewed in [8]).  The antagonism by Mxi1 on the molecular level correlated 
well with its ability to be a potent suppressor of Myc transformation activity in the rat embryo 
fibroblast (REF) assay, a surrogate assay for neoplastic transformation [10].   Interestingly, a 
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naturally occurring mouse Mxi1 protein isoform lacking the Sin3 recruitment domain (a.k.a. 
the SID), called Mxi1-WR, was unable to potently suppress Myc cotransformation activity in 
the REF assay [10].  This suggested that Myc antagonism and growth suppression was linked 
to the presence of a SID and its ability to recruit co-repressors. 
Recently, our group and others have recognized that in addition to the Mxi1-WR 
isoform, other Mxi1 protein isoforms exist both in mouse and man [12-14].  Many of these 
isoforms appear to arise from alternative exon 1 (and promoter) usage within the mxi1 
genomic locus.  One new isoform that we have described, Mxi1-SRα, exhibits many of the 
biological properties attributed originally to Mxi1 and outlined above (we have renamed the 
original Mxi1 isoform Mxi1-SRβ) [12].  Specifically, Mxi1-SRα can also bind to Max and to 
Sin3, and can function as a transcriptional repressor upon various reporter plasmids including 
synthetic E-box reporters.  With respect to expression profiles, Mxi1-SRα and Mxi1-SRβ 
transcripts can be found together in the majority of newborn and adult mouse tissues 
examined on the gross level.  However, tissue-specific expression patterns were also 
observed, including that Mxi1-SRα appears to be the predominant transcript in the adult 
intestine and in the developing embryo, while Mxi1-SRβ transcripts predominate in the adult 
liver and kidney [12].   
In our initial description of Mxi1-SRα and its comparison to Mxi1-SRβ [12], we 
speculated that despite their apparent functional overlap in the assays employed in that study, 
the possibility existed for distinct functions for these two isoforms.  In the present study, we 
have compared further the Mxi1-SRα and Mxi1-SRβ isoforms at the levels of Myc 
antagonism in the REF assay, subcellular localization, and transcriptional activity. Some of 
these analyses have assigned differential functions to the two isoforms, and we show that the 
unique amino terminal extension on Mxi1-SRα contributes to these differences. A possible 
basis for these differences may lie in the ability of Mxi1-SRα (but not of Mxi1-SRβ) to 
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recruit specific protein partners such as the nuclear GAPDH protein. 
 
Results 
 
Mxi1-SRα   lacks the strong suppressive activity of Mxi1-SRβ in the REF assay 
In our earlier report describing Mxi1-SRα, this isoform appeared functionally 
homologous to Mxi1-SRβ in that both could bind to Max and Sin3 and repress both basal and 
Myc- activated transcription of various reporter plasmids [12].  Based on these properties, we 
predicted that Mxi1-SRα would act like its Mxi1-SRβ counterpart to suppress Myc+Ras 
cotransformation activity in the REF assay.  Expression constructs were generated encoding 
Myc-tagged versions of these two isoforms, as well as of the Mxi1-WR isoform that lacks the 
SID, and shown to give rise to proteins of the expected size expressed at similar levels (Fig. 
1A). Each of these constructs (or empty vector) was introduced along with Myc and Ras into 
primary REFs, and the extent of foci formation was assessed ~10 days post-transfection.  As 
shown in Figure 1B, the addition of Mxi1-SRβ to Myc+Ras transfections resulted in the 
expected 5-fold reduction in foci number relative to that obtained in the Myc+Ras+empty 
vector point (compare Fig. 1B black “SRβ” bar to Fig. 1B open “empty” bar; see also [10]).  
Surprisingly, the addition of Mxi1-SRα to Myc+Ras transfections resulted in at best a 2-fold 
reduction in foci number relative to the Myc+Ras+empty vector point (compare Fig. 1B grey 
“SRα” bar to Fig. 1B open “empty” bar).  Indeed, Mxi1-SRα behaved comparably to Mxi1-
WR in these assays (compare Fig. 1B grey “SRα” bar to Fig. 1B dotted “WR” bar).  This was 
unexpected given that (i) the inability of Mxi1-WR to potently suppress Myc co-
transformation has been attributed to its lack of a SID [10] and (ii) Mxi1-SRα harbors a Sin3-
interacting SID that is ~70% homologous to the SID of Mxi1-SRβ [12].    
We considered the possibility that the difference in suppression potential between 
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introduced Mxi1-SRα and Mxi1-SRβ could relate to disparities in their expression levels at 
the onset of foci formation.  As such, we generated several expression constructs for Mxi1-
SRα containing different lengths of 5’UTR, and tested these in in vitro 
transcription/translation assays followed by Western blotting, and in the REF assay (data not 
shown).  Many of these constructs produced levels of Mxi1-SRα protein comparable to or 
greater than those of Mxi1-SRβ, yet they could still not potently suppress in the REF assay.  
To address this in another way, we tested whether the introduction of lower amounts of 
Mxi1-SRβ would compromise its suppression potential.  Introduction of one-fifth the usual 
amount of Mxi1-SRβ to Myc+Ras transfections resulted in the same 5-fold reduction in foci 
formation observed with the usual dose of Mxi1-SRβ (compare Fig. 1B black “SRβ low” bar 
to Fig. 1B black “SRβ” bar).  Together, these findings suggested that the differential effects 
of Mxi1-SRα and Mxi1-SRβ in the REF assay likely relate to variables aside from expression 
levels. 
As another gauge of suppression potential, we examined the introduced Mxi1 
isoforms in stable transformed cell lines established from foci that had emerged in the various 
transfection points of the REF assay (Fig. 1C).  Transformed cell lines established from the 
Myc+Ras+Mxi1-SRα points consistently expressed detectable levels of introduced Mxi1-
SRα as assessed by Western blotting analysis (Fig. 1C, arrowed ~52 kDa band in lanes α1 
and α2 in comparison to corresponding area in lane E1 which is from cell lines established 
from the Myc+Ras+empty vector point).  Once again, this finding of expressed exogenous 
Mxi1-SRα resembled what is seen with the SID-less Mxi1-WR isoform as we have reported 
previously [10].  In contrast, transformed cell lines established from the Myc+Ras+Mxi1-
SRβ points failed to express detectable levels of introduced Mxi1-SRβ (Fig. 1C, lanes β1 and 
β2; and see also [10]).  These results suggest that strong selective pressure against the 
expression of introduced Mxi1-SRβ, but not of Mxi1-SRα (or Mxi1-WR), exists during the 
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course of cellular transformation induced by Myc. 
 
Mxi1-SRα   appears to be localized to the nucleus like Mxi1-SRβ  
 The findings of the REF assay suggested that Mxi1-SRα and Mxi1-SRβ may encode 
differential functions with respect to their ability to antagonize Myc function.  As a first 
attempt to uncover the molecular basis for this difference, we performed immunofluorescence 
assays on three different cell types after transfection with Myc or FLAG-tagged versions of 
Mxi1-SRα or Mxi1-SRβ (Fig. 2A).  As shown in Figure 2B, Myc-tagged Mxi1-SRα and 
Myc-tagged Mxi1-SRβ each exhibit speckled nuclear staining in transfected U20S cells.  
Similar results were obtained after transfection of U20S cells with the Flag-tagged isoforms, 
as well as after transfection of any of these constructs into COS7 or NIH3T3 cells (Fig. 2C 
and data not shown). It should be noted that this Mxi1-SRα subcellular localization is not in 
complete agreement with a previous report from another group [13] which described a 
primarily cytoplasmic localization, with some nuclear staining as well. However, Mxi1-SRα 
is predicted to be nuclear by programs such as PSORT II (reliability 94.1% by the [15]). Due 
to the lack of available Mxi1 isoform-specific antibodies, we cannot determine the 
localization of the endogenous forms by immunofluorescence at this time. 
Based on the data presented in Figure 2, we believe that exogenous Mxi1-SRα, like 
Mxi1-SRβ, is a nuclear protein.  Thus, difference in the subcellular localization cannot 
provide a basis for the differential effect of the two isoforms on Myc induced cellular 
transformation.  
 
The evolutionarily conserved, extended proline-rich domain of Mxi1-SRα  affects its 
suppression potential 
We predicted that the basis for functional differences between Mxi1-SRα and Mxi1-
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SRβ could relate to the unique amino terminal 61 amino acid (aa) extension on Mxi1-SRα 
(preceding its SID).  As shown in Figure 3A, this extension (here named the PRD for proline-
rich domain) is conserved from fish to man, and, at least in mammals, is proline and alanine 
rich. Hypothesizing that this PRD of Mxi1-SRα could be playing a regulatory role or 
encoding novel functions, we asked whether the presence of this domain is responsible for 
the differential effects of introduced Mxi1-SRα and Mxi1-SRβ in the REF assay. An 
expression construct was generated encoding a Myc-tagged version of Mxi1-SRα lacking its 
proline-rich domain (Fig. 3B); this construct was shown to give rise to a protein of the 
expected size expressed at similar levels to its full length counterpart (data not shown).  
When introduced with Myc+Ras in the REF assay, this construct suppressed co-
transformation activity at least as well as Mxi1-SRβ (Fig. 3B, compare striped “SRαΔPRD” 
bar to black “SRβ” bar). Said another way, deletion of the 61 amino acid PRD from Mxi1-
SRα converts Mxi1-SRα into a potent suppressor of Myc+Ras transformation. However, the 
PRD does not appear sufficient on its own to convert the Mxi1-SRβ  protein into a 
protein with α-like properties in other assays (see below). 
 
The extended proline-rich domain of Mxi1-SRα  affects its activity on the MYC  promoter  
 Having seen this effect of the proline-rich domain on Mxi1-SRα function at the 
cellular level, we next asked whether the presence or absence of this domain affects Mxi1-
SRα activity on the promoters of downstream target genes. Earlier we had shown that Mxi1-
SRα and Mxi1-SRβ exhibited similar effects on two synthetic reporter constructs in 293T 
cells [12]. Here we extended these analyses to the E-box containing promoter ornithine 
decarboxylase (ODC) promoter; notably this is one of the few promoters reported to be 
regulated by Mxi1 (and also by Myc) [16].  As shown in Figure 4A, the addition of Mxi1-
SRα or Mxi1-SRβ effectors to 293T cells also carrying ODC-driven luciferase resulted in a 
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2-3-fold reduction in luciferase activity, consistent with what has been shown previously for 
Mxi1-SRβ on this promoter [16]. It is known that this region of the ODC promoter bears two 
E-box elements that are repressed by Mxi1 but activated by Myc (see [17] for example). As 
such, the similar effects of the two Mxi1 isoforms on this promoter are in the line with their 
similar effects on the synthetic E box reporter [12].   
 A second promoter shown previously to be regulated by Mxi1-SRβ is the MYC 
promoter [18,19]. For this promoter, regulation by Mxi1 has been proposed to occur not 
through E-box sequences but through initiator (Inr) elements and possibly also E2F binding 
sites present in cis [18,19]. Whether the action of Mxi1-SRβ  on the MYC promoter is 
direct or indirect remains to be elucidated. Consistent with what has been reported 
previously, Mxi1-SRβ exhibited a mild, but reproducible, repressive effect on the full length 
human c-MYC promoter (Fig. 4B) [18,19].  Surprisingly, Mxi1-SRα activated this reporter 
(Fig. 4B). Deletion of the 61 amino acid PRD from Mxi1-SRα converted Mxi1-SRα from an 
activator to a potent repressor of the MYC promoter (Fig. 4B). Again, whether the action of 
Mxi1-SRα  is direct or indirect remains to be elucidate. Of note, the same trend of Mxi1-
SRβ and Mxi1-SRαΔPRD repressing, but Mxi1-SRα activating, was observed on the 
minimal MYC-P1P2 promoter (data not shown). Taken together, our findings suggest that on 
certain downstream target gene promoters in transient transfection experiments, Mxi1-SRα 
and Mxi1-SRβ exhibit distinct transcriptional effects, and these are correlated with the 
presence of the proline-rich domain on Mxi1-SRα.  
 
Mxi1-SRα  is able to interact with GAPDH, and these two proteins synergise to activate the 
myc promoter  
We hypothesized that the basis for the differential effects of Mxi1-SRα and Mxi1-SRβ in 
several functional assays could relate to differences in their protein interaction profiles. To 
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address this, we established inducible HeLa cell lines expressing FLAG-Mxi1-SRα or 
FLAG-Mxi1-SRβ under the control of the TET ON promoter. We monitored induction as 
well as expression levels of the isoforms by immunoprecipitation with an anti-FLAG 
antibody followed by anti-FLAG Western blot analysis (Fig.5A). We then performed a 
FLAG pull down analysis, followed by resolution on SDS-PAGE gel and silver staining (see 
Fig. 5B). Several bands appearing to be present in the Mxi1-SRα but not Mxi1-SRβ lanes 
were subjected to mass spectrometry analysis (see Material and Methods). One candidate 
Mxi1-SRα interacting protein identified was the 38kDa GAPDH protein which obtained a 
very high score with 31 matching peptides (Data not shown). This interaction was 
confirmed by Western blotting analysis using the anti-GAPDH antibody [20] on the FLAG 
immunoprecipitates (Fig. 5C). Interestingly, this 38 kDa GAPDH protein has recently been 
characterized to be part of a transcriptional co-activator complex [20]. Accordingly, we next 
tested whether Mxi1-SRα and GAPDH could synergize to activate the myc promoter. 
Whereas GAPDH overexpression had no activating effect on the P1P2myc promoter without 
effector (Fig. 5D, compare lane 2 with lane 1) or even in the presence of Mxi1-SRβ (Fig. 5D, 
compare lane 5 and 6 with lane 1), the co-expression of GAPDH with Mxi1-SRα led to 
enhanced activation (Fig. 5D, compare lane 4 with lane 3). Very interestingly, GAPDH 
over expression did not affect the activity of the Mxi1-SRα  protein when its PRD was 
deleted (Fig. 5D, compare lane 7 and 8 with lane 1). Thus, all the specific properties of 
the full length Mxi1-SRα  protein observed here appears to depend on the presence of 
the PRD.  Taken together, it appears that Mxi1-SRα may recruit a unique set of proteins, 
including GAPDH, to participate in transcriptional activation of target genes. 
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Discussion 
 
In this study, we have further compared the Mxi1-SRα and Mxi1-SRβ protein 
isoforms that have previously been described by us to be highly similar at the levels of tissue-
type expression patterns, protein interaction profiles, and transcriptional repression activity 
[12].  Here we extend the similarity between these isoforms by showing that, at least when 
exogenously introduced, both isoforms localize to the nucleus (Figure 2) and both repress the 
promoter of a known Mxi1 (and Myc) downstream gene target, ODC (Figure 4A).  However, 
Mxi1-SRα and Mxi1-SRβ also appear to encode differential functions, and those revealed in 
this study relate to two distinct levels of Myc antagonism.  First, contrary to Mxi1-SRβ, 
Mxi1-SRα is not a potent suppressor of the cellular transformation activity of Myc (Figure 
1).  Second, while Mxi1-SRβ has a mild, but reproducible repressive effect on the MYC 
promoter in transient expression assays, Mxi1-SRα instead activates this promoter (Figure 
4B). 
The finding of these differential functions is in line with the dogma that the proteome 
gains functional complexity by encoding multiple isoforms of a given protein, with these 
isoforms having shared and distinct features (reviewed in [21,22]).  With respect to Mxi1-
SRα and Mxi1-SRβ, this functional complexity may allow for differential regulation of Myc-
dependent processes. This could occur via alterations in the balance between the two 
isoforms in specific cell types, developmental stages, or even during cancer pathogenesis.  
Regarding the latter, it is interesting to note that the Mxi1-SRα isoform (also know as Mxi1-
0) was cloned initially as a gene upregulated in a neuroblastoma cell line. Moreover, in that 
study, the ratio between Mxi1-SRα/Mxi1-0 and Mxi1-SRβ in primary glioblastomas was 
shown to be increased relative to their ratio in normal brain [13].  Future studies using 
isoform-specific reagents could determine whether this also holds true for other cancer types, 
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and could ascertain whether altering the levels of Mxi1-SRα or Mxi1-SRβ can differentially 
impact upon cellular processes including proliferation, apoptosis, differentiation, etc.  
Isoforms of numerous proteins have been studied and compared in this manner, including 
alternative isoforms of members of the p53/p63/p73 (reviewed in [23]) and the Bcl2 families 
(reviewed in [24]).  
On the molecular level, we show that the unique proline rich domain (PRD) on Mxi1-
SRα contributes to the differential functions of Mxi1-SRα and Mxi1-SRβ in Myc antagonism 
Deletion of this domain converts Mxi1-SRα into a potent suppressor of Myc/Ras 
cotransformation activity (Figure 3) and also changes Mxi1-SRα’s activity on the MYC 
promoter from activation to repression (Figure 4B). Relevant to this, we were intrigued by the 
proline-rich composition of the PRD of Mxi1-SRα, given that this is a recurring feature of 
transactivation domains. However, when we tested the PRD in the Gal4 heterologous reporter 
assay system, we did not observe it to have inherent transactivation potential ([12] and data 
not shown). Thus the PRD is necessary but likely not sufficient for the transactivation activity 
of Mxi1-SRα. Consistent with this, a chimeric protein that we generated to contain the PRD 
hooked up to the Mxi1-SRβ isoform (PRD-Mxi1-SRβ) is not able to activate a myc promoter 
in transient transfection experiment (data not shown). Thus, the activation function of Mxi1-
SRα  that depends on the integrity of the PRD appears to depend also on other features of 
the Mxi1-SRα proteins as it cannot be simply transferred to another protein, even as 
closely related as Mxi1-SRβ  
We speculate that the PRD may be involved in regulating other functional domains of 
Mxi1 (e.g., the SID or the bHLH/LZ) and/or in the recruitment of other activities.  However, 
in some assays, the presence of this domain does not appear to distinguish Mxi1-SRα from 
Mxi1-SRβ (this study and [12]).  This suggests that the effects of the proline-rich domain are 
context sensitive, and could depend on variables including cellular milieu and promoter 
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environment. It is of interest in this regard that, in our hands, Mxi1-SRα and Mxi1-SRβ 
behaved similarly on E-box containing promoters which are thought to be repressed by Mxi1 
(and related Mad family members) in a basic region-, Max-, and Sin3-dependent manner (for 
example see [16]; also see [25]).  In contrast, on the MYC promoter which is repressed by 
Mxi1-SRβ in an E-box-independent manner ([18,19]), Mxi1-SRα exerts distinct effects.  It is 
possible that this differential regulation of target genes contributes to different biological 
outcomes including the effect on transformation we have observed in the REF assay (Figure 
1).  A very analogous scenario has been described recently for isoforms of the Wilms’ tumor 
gene WT1.  A newly identified WT1 isoform (WT1s) has been shown to arise from 
alternative promoter/leader exon utilization, similar to how Mxi1-SRα and Mxi1-SRβ arise.  
While the full length WT1 protein encodes both transcriptional repression and activation 
domains, WT1s lacks the repression domain and consequently has different effects on 
downstream targets and in growth/cancer-related assays [26]. 
Our Flag pull down analysis showed that Mxi1-SRα, but not Mxi1-SRβ, is able to 
recruit nuclear GAPDH (Figure 5B and 5C). Moreover, GAPDH seems to enhance the 
activating potential of Mxi1-SRα on the myc promoter, but has no effect on the repression 
effect of Mxi1-SRβ or a Mxi1-SRα  protein deleted from its PRD (Figure 5D). 
Interestingly, nuclear GAPDH/p38 has been shown previously to be recruited by Oct-1 in a 
co-activator complex implicated in the S phase transcription of histone H2B promoter [20]. 
Thus, it is tempting to speculate that Mxi1-SRα may be able to recruit co-activator 
complexes containing GAPDH to specific target genes resulting in activation. More and more 
reports suggest that GAPDH is a multifunctional protein displaying diverse activities distinct 
from its conventional glycolytic activity. For example, it has been shown to be able to 
regulate cyclin B-cdk1 activity via its interaction with the protein SET [27], to induce the 
pro-apoptotic mitochondrial membrane permeabilization which is essential for apoptosis [28] 
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or to prevent down-regulation of CSF-1 protein by binding to CSF-1 AU-rich element and 
thus increasing metastatic properties in ovarian cancer [29]. GAPDH is an abundant protein 
but its participation in many different complexes in different cellular compartment could 
make it limiting for some of its roles. Thus, some specific functions of GAPDH could be 
more sensitive than other to variation in its intracellular level or availability. Our observation 
that overexpression of GAPDH enhance the activity of overexpressed Mxi1-SRα indicates 
that it is indeed not present in sufficient amounts for Mxi1-SRα function. In this respect, we 
tested if the GAPDH protein could be the limiting factor preventing the PRD alone from 
having a transcriptional activity by itself in the gal4 assay (data not shown) and we 
found that even in the presence of overexpressed GAPDH, the PRD was not sufficient to 
activate transcription, emphasizing the contribution of other features of the Mxi1-
SRα  protein. 
In the future, it would be important to uncover the full spectrum of differentially 
interacting proteins as well as the spectrum of downstream target genes regulated by Mxi1-
SRα and/or Mxi1-SRβ, and assess the transcriptional effects of these isoforms on these 
targets. A better molecular grasp on these Mxi1 isoforms is necessary for understanding the 
precise role(s) of Mxi1 within the extended Myc network and in the context of development 
and cancer.  
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Materials and Methods 
Plasmid Generation 
The Myc-tagged Mxi1-SRα and Mxi1-SRβ constructs were described in [12], and the Myc 
and Ras expression constructs and the pvNic vector were described in [10]. The Myc tagged 
WR expression construct was generated by introducing the WR cDNA containing the full 
5’UTR in pcDNA3.1. The coding region of Mxi1-SRα and Mxi1-SRβ were subcloned by 
PCR in a vector containing an amino terminal flag tag. The Mxi1-SRα ΔPRD expression 
construct corresponds to the full Mxi1-SRα deleted for its first 61amino acids. The ODC and 
MYC reporter constructs were kind gifts of Dr. John Cleveland and Dr. Linda Penn, 
respectively. The HA-GAPDH expression vector was obtained by amplifying GAPDH cDNA 
by RT-PCR on RNA from HeLa cells, followed by subcloning in an HA-tag-containing 
expression vector. The Tet responsive Mxi1-SRβ and -SRα expression constructs were 
generated by cloning the FLAG–Mxi1 fusion protein behind a tet responsive promoter. 
Further details of plasmids constructions are available upon request. 
REF assay and foci studies 
Primary REFS were prepared and transfected using calcium phosphate precipitation as 
described [30].  For each construct listed, 2µg was used per plate except in the “SRβ low” 
point where only 0.4µg of plasmid DNA was used. The number of foci obtained for each 
plate was counted 10-15 days after transfection. Individual foci were picked, subcloned, and 
expanded as described [30]. 
Immunofluorescence 
U2OS cells were transfected with 100 ng of DNA with Fugene, and immunofluorescence was 
performed as described in [31] using the anti-FLAG (M2, Sigma-Aldrich, St Louis, MO, 
USA) or the anti-myc (Upstate, Millipore, Bedford, MA, USA) primary antibodies and the 
anti-rabbit coupled to FITC (Jackson Immuno Research) or the anti-mouse coupled to FITC 
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(Jackson Immuno Research, West Grove, PA, USA) secondary antibodies, respectively. 
Images were acquired with an Olympus BX61 epifluorescence microscope (Olympus 
America, Melville, NY) and a Roper Scientific CoolSNAP HQ camera (Roper Scientific, 
Tucson, AZ). 
Transcriptional reporter assays 
293T cells were transfected by the calcium phosphate precipitation method, and luciferase 
activity was assessed 48 hours post transfection as described in [12]. The luciferase values 
were normalized to protein concentration as assessed by a Bradford assay. 
Protein preparation and Western blotting analysis 
Protein preparation and Western blotting analysis were performed as described in [12]. In 
vitro transcription/translation was performed using the TNT transcription / translation system 
(Promega, Madison, WI, USA). 
Establishment of inducible cell lines 
HeLa TET ON cells (Clontech, Takara, Mountain View, CA, USA) were transfected with 
inducible constructs expressing FLAG-Mxi1-SRα, FLAG-Mxi1-SRβ or empty vector using 
Fugene. Three days after transfection, cells were selected using puromycin (1µg/mL), and on 
day 15 post-transfection clones were picked and expanded. After induction with doxycycline 
(1µg/mL), the individual clones were tested for their expression of the protein of interest. 
Flag pull down / Silver Staining / Mass spectrometry Analysis 
For each stable cell line, ten 15-cm-diameter plates at 80% confluence were induced with 
doxycycline (1µg/mL) for 24h. Immunoprecipitation was performed using the FLAG agarose 
antibody (Sigma #A2220) in 50mM Tris pH 7.5, 150 mM NaCl, 0.5% NP40, 5 mM EDTA 
and 1 mM DTT. The immunoprecipitated protein was eluted from the beads according to the 
Manufacter’s instruction and the supernatant was run on a 12% SDS-PAGE gel. Silver 
staining of the gel was performed as described in [32]. Mass spectrometry was performed by 
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the Rockefeller University Proteomics Resource Center (New York).  
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Titles and legends to figures 
 
Figure 1: Contrary to Mxi1-SRβ, Mxi1-SRα is not a potent suppressor of cellular 
transformation by Myc and Ras. 
A) (upper) Schematic representation of the different Mxi1 isoforms tested for suppressive 
potential in the Rat Embryo Fibroblast (REF) Transformation Assay.  All of the isoforms 
carried Myc tags on their COOH termini. SID=Sin3 interacting domain; BR=basic region; 
HLH=helix-loop-helix; CT=carboxyl terminus. (lower) Western blotting analysis of in vitro 
transcription/translation reactions performed on plasmids encoding the tagged Mxi1 isoforms 
shown, probed with the anti-Myc tag antibody.  Molecular weight is shown in kDa on the 
right. The sample in the first lane represents an in vitro transcription/translation reaction in 
which there was no input plasmid. Of note, a doublet is often detected in the Mxi1-SRα lane; 
this likely results from an alternative initiation of translation with an in-frame ATG located 
78 base pair downstream of the first ATG. B) Graphic representation of the results obtained 
in the REF assay expressed as % of foci formation, with the level of foci formation obtained 
for the empty vector control point set to 100%. In the SRβlow point, one-fifth the usual 
amount of SRβ expression construct was introduced. The graph shows the results of one 
representative experiment out of 2 experiments performed, giving similar results. C) Western 
blotting analysis of whole cell lysates made from transformed cell lines generated from foci 
arising in the REF assay.  E1 is from a Myc+Ras+empty vector point, α1 and α2 are from 
Myc+Ras+Mxi1-SRα points, and β1 and β2 are from Myc+Ras+Mxi1-SRβ points.  The 
SRα-myc and SRβ-myc lanes represent control lysates derived from 293T cells 
overexpressing Mxi1-SRα-myc and Mxi1-SRβ-myc, respectively.  The blot was probed with 
the anti-Myc tag antibody. The arrow marks the Mxi1-SRα-myc protein observable in 
established cell lines derived from Myc+Ras+Mxi1-SRα foci. Molecular weight is shown in 
kDa on the right.  
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Figure 2: Introduced Mxi1-SRα and Mxi1-SRβ each localize to the nucleus. 
A) Schematic representation of the constructs used for the immunolocalization experiments 
shown in B and C. Note that the Myc-tagged isoforms carry the tag on their COOH termini, 
while the FLAG-tagged isoforms carry the tag on their NH2 termini. B) U2OS cells were 
transfected with the Myc-tagged constructs indicated on the left, and the introduced Mxi1 
isoforms were detected by indirect immunofluorescence using the rabbit anti-Myc antibody 
(Upstate # 06-549) as primary antibody and anti-rabbit coupled to FITC as secondary 
antibody (Jackson ImmunoResearch, WestGrove, PA).  C) U2OS cells were transfected with 
the FLAG-tagged constructs indicated on the left, and the introduced Mxi1 isoforms were 
detected by indirect immunofluorescence using the mouse anti-FLAG antibody (Sigma # 
F3165) as primary antibody and anti-mouse coupled to FITC as secondary antibody (Jackson 
ImmunoResearch, WestGrove, PA).  Note that in (B) and (C), while DAPI labels all of the 
cell nuclei (see also phase images), only some of the cells express the introduced Mxi1 
proteins, and in these the subcellular localization is nuclear. This experiment was 
performed 3 times, each giving similar results. 
 
Figure 3: An Mxi1-SRα protein deleted for its proline-rich domain is able to potently 
suppress cellular transformation by Myc and Ras. 
A) Alignment of the proline-rich domains of various Mxi1-SRα orthologs showing the 
conservation of this domain throughout evolution.  The Mxi1 protein sequences were derived 
from the following Genbank entries: D. rerio (XP_709796); C. familiaris (XP_852395); M. 
musculus (BAE32663; also the 295 aa protein encoded by BC064453); and H. sapiens 
(NP_569157).  Note that the D. rerio sequence is extended relative to that reported by us 
previously [33].  Alignments were performed using the Multalin program [34]. B) (top) 
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Schematic representation of the synthetic Mxi1-SRα ΔPRD construct (Mxi1-SRα deleted of 
its proline-rich domain) compared to the Mxi1-SRα construct represented as in figure 1A. 
(bottom) Graph of the results obtained in the REF assay expressed as % of foci formation, 
with the level of foci formation obtained for the Myc+Ras+empty vector control point set to 
100%. The graph shows the results of one representative experiment of a total of 3 
experiments performed, each giving similar results.  
 
Figure 4: Common and distinct transcriptional effects of Mxi1-SRα and Mxi1-SRβ on 
downstream target gene promoters. 
A) (left) Graphic representation of the results from a luciferase assay performed using the 
ODC-LUC reporter (schematic representation on top) and the Mxi1-SRβ or Mxi1-
SRα effectors.  Data, graphed in a log2 scale, show fold repression relative to that obtained 
with an empty vector effector (“empty” lane) which is set to 0.   (right) Western blotting 
analysis using a rabbit anti-myc tag antibody to assess the expression levels of the different 
myc tagged effector constructs from the actual experiment graphed in (A). Molecular weight 
is shown in kDa on the right. B) (left) Graphic representation of the results from a luciferase 
assay performed using the MYC-LUC reporter (schematic representation on top) and the 
Mxi1-SRβ, Mxi1-SRα, or  Mxi1-SRα ΔPRD effectors.  Data, graphed in a log2 scale, show 
fold activation or repression relative to that obtained with an empty vector effector (“empty” 
lane) which is set to 0.   (right) Western blotting analysis using a rabbit anti-myc tag antibody 
to assess the expression levels of the different myc tagged effector constructs from the actual 
experiment graphed in (B). Molecular weight is shown in kDa on the right. The experiments 
shown are representative examples of experiments performed at least 4 independent times, 
with each point done in triplicate each time.  
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Figure 5: Mxi1-SRα, but not Mxi1-SRβ, is able to recruit GAPDH and to synergize with 
GAPDH in activating the myc promoter. 
A) anti-FLAG Western Blot (WB) of an anti-FLAG Immunoprecipitation (IP) performed on 
lysates from HeLa Tet ON cells expressing either empty vector, FLAG-Mxi1-SRα or FLAG-
Mxi1-SRβ  after 24h induction  with 1µg/mL doxycycline (lanes labeled +) or without 
induction (lanes labeled -). Note that the induction is tightly controlled as there is no Mxi1 
produced in the absence of Doxycycline.  B) Silver staining of an anti-Flag IP performed on 
lysates from HeLa Tet ON cells expressing either empty vector, FLAG-Mxi1-SRα or FLAG-
Mxi1-SRβ  after 24h induction with 1µg/mL doxycycline. The position of the GAPDH band 
(specific to the Flag-Mxi1-SRα lane) that was subjected to Mass spectrometry analysis is 
shown with an arrow. C) anti-p38/GAPDH (a kind gift of Dr. Roeder) WB of an anti-FLAG 
IP performed on lysates from HeLa Tet ON cells expressing either empty vector, FLAG-
Mxi1-SRβ or FLAG-Mxi1-SRα  after 24h induction with 1µg/mL doxycycline. The GAPDH 
band is shown with an arrow. D) Graphic representation of a luciferase assay performed with 
the P1P2 c-myc promoter as the reporter construct and the HA tagged expression construct of 
p38/GAPDH and/or the myc tagged expression vectors of Mxi1-SRβ, Mxi1-SRα and Mxi1-
SRα  deleted from its PRD. Mxi1-SRα and Mxi1-SRβ are not regulating the P1P2 promoter 
as extensively as the full length myc promoter, which makes the P1P2 promoter more 
sensitive to the variation in GAPDH levels provided by transfection. The data show fold 
activation relative to empty vector. The experiment shown is a representative experiment of 
an experiment done 3 times where each point was done in triplicate.  
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